GTx Inc. (GTXI) announced Monday morning that it received a Complete Response Letter issued from the FDA, regarding its New Drug Application for toremifene 80 mg. The letter recommended that more data be provided to the FDA. GTx Inc. gapped open sharply lower Monday and declined throughout the second half of the morning. Shares finished down by $4.42 at $4.56 on the highest volume of the year. The stock sank beneath support and closed at a new low for the year.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.